Citius Oncology, Inc. (CTOR) - 10-Q Summary
Business Context and Reporting Period
Company: Citius Oncology, Inc.
Reporting Period: Quarter and six months ended March 31, 2026.
Business Overview: A specialty biopharmaceutical company focused on the commercialization of LYMPHIR (denileukin diftitox), an immunotherapy for cutaneous T-cell lymphoma (CTCL). Commercial revenue commenced in December 2025. The company is a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2026 | Six Months Ended Mar 31, 2026 | Balance Sheet (Mar 31, 2026) |
|---|---|---|---|
| Revenue | $1.67 million | $5.61 million | N/A |
| Gross Profit | $1.34 million (80% margin) | $4.49 million (80% margin) | N/A |
| Net Loss | $(26.61) million | $(32.14) million | N/A |
| Operating Expenses | $29.95 million | $38.36 million | N/A |
| Cash & Equivalents | N/A | N/A | $2.63 million |
| Working Capital | N/A | N/A | $(29.39) million (Negative) |
| Total Liabilities | N/A | N/A | $65.43 million |
| Stockholders' Equity | N/A | N/A | $35.27 million |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $1.67 million in revenue for the quarter and $5.61 million for the six months, compared to $0 in the prior year periods, following the December 2025 commercial launch of LYMPHIR.
- Operating Expenses Surge: Operating expenses increased significantly to $29.95 million (Q2) and $38.36 million (6M) from $7.47 million and $13.87 million in the prior year periods, respectively. This increase was primarily driven by a $19.73 million contract cancellation fee recorded in March 2026 following the termination of a bulk drug substance manufacturing agreement due to payment breaches.
- Amortization: Amortization of in-process research and development (IPR&D) began in December 2025, resulting in $1.72 million (Q2) and $2.29 million (6M) in expenses, compared to $0 previously.
- Stock-Based Compensation: Increased to $3.53 million (Q2) and $7.48 million (6M) due to restricted stock unit awards granted in September 2025.
- One-Time Gain: Recognized a $1.76 million gain from the sale of New Jersey net operating losses.
Outlook, Risks, and Subsequent Events
- Going Concern: The filing includes a "substantial doubt" regarding the company's ability to continue as a going concern. Management expects funds to last through November 2026 but requires additional capital thereafter.
- Recent Financing (Subsequent Events):
- May 5, 2026: Received ~$11.5 million from warrant exercises via an inducement transaction.
- May 6, 2026: Entered a loan agreement for up to $25.0 million; $10.0 million funded immediately. Interest rate is Prime + 6% or 12.75% (whichever is higher). Maturity is November 1, 2029.
- Nasdaq Compliance: Received notice on April 22, 2026, of non-compliance with the $1.00 minimum bid price rule. The company has 180 days (until October 19, 2026) to regain compliance.
- Commercial Progress: Initial shipments to Europe began in April 2026. Positive topline results were announced for investigator-initiated trials in DLBCL and gynecologic cancers.
- Supply Chain: The company is evaluating new contract manufacturing organizations (CMOs) following the termination of the previous agreement. Management anticipates no interruption in supply.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $11.5M warrant proceeds and $10M loan tranche to cover the $29.4M negative working capital and ongoing burn rate through November 2026.
- Manufacturing Continuity: Confirm the execution of a new CMO agreement by June 30, 2026, to ensure uninterrupted supply of LYMPHIR.
- Debt Obligations: Review the terms of the new $25M loan, specifically the milestone triggers for Tranches 2 and 3, and the conversion option for the lender.
- Revenue Sustainability: Assess whether the initial 80% gross margin and early adoption metrics (83% formulary uptake) can scale to offset the high fixed costs and royalty obligations (10-15% to Dr. Reddy's).
- Nasdaq Status: Monitor stock price performance to ensure compliance with the $1.00 minimum bid price requirement by October 2026.